Novavax, Inc.
NVAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,224 | $484 | $804 | $10,644 |
| - Cash | $530 | $569 | $1,337 | $1,515 |
| + Debt | $230 | $229 | $550 | $454 |
| Enterprise Value | $924 | $144 | $17 | $9,583 |
| Revenue | $682 | $556 | $1,599 | $198 |
| % Growth | 22.6% | -65.2% | 709.3% | – |
| Gross Profit | $479 | $213 | $696 | $198 |
| % Margin | 70.3% | 38.2% | 43.5% | 100% |
| EBITDA | -$108 | -$487 | -$605 | -$1,681 |
| % Margin | -15.8% | -87.6% | -37.8% | -850.7% |
| Net Income | -$187 | -$545 | -$658 | -$1,744 |
| % Margin | -27.5% | -98% | -41.1% | -882.5% |
| EPS Diluted | -1.23 | -5.41 | -8.42 | -23.44 |
| % Growth | 77.3% | 35.7% | 64.1% | – |
| Operating Cash Flow | -$87 | -$714 | -$416 | $323 |
| Capital Expenditures | -$13 | -$59 | -$93 | -$57 |
| Free Cash Flow | -$100 | -$773 | -$509 | $265 |